Dyne Therapeutics (DYN) announced that the Ministry of Health, Labour and Welfare in Japan has granted Orphan Drug designation for DYNE-251 in individuals with Duchenne muscular dystrophy who have mutations in the DMD gene that are amenable to exon 51 skipping. DYNE-251 is being evaluated in the Phase 1/2 DELIVER clinical trial.
Doug Kerr, chief medical officer of Dyne, said: "With orphan drug designation now granted in Japan, complementing existing designations in the U.S. and Europe, DYNE-251 continues to advance as a promising next-generation exon 51 skipping therapy."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.